Korro Bio Earnings Call Transcripts
Fiscal Year 2026
-
KRRO-121, a novel RNA editing therapy, is advancing toward clinical trials for ammonia control in UCD and HE, with strong preclinical efficacy, a favorable safety profile, and a large addressable market. Regulatory filing is expected in the second half of 2026.
-
The presentation detailed advances in RNA editing for both rare and prevalent diseases, highlighting a lead program targeting ammonia reduction and a next-generation Alpha-1 candidate nearing clinical nomination. Strategic pivots and platform improvements have accelerated development and expanded the pipeline.
Fiscal Year 2025
-
The company is advancing RNA editing therapies for chronic diseases, with lead asset KRRO-110 showing high in vivo editing rates and strong preclinical results. Regulatory engagement is ongoing, with pivotal trial guidance expected next year. Financial runway extends into 2027, supported by partnerships.
-
The conference highlighted a modular RNA-editing platform advancing three programs, with KRRO-110 for Alpha-1 antitrypsin deficiency leading in clinical trials. Interim safety and efficacy data are expected this year, and the company projects a $3B U.S. market opportunity.
-
A novel RNA editing platform is advancing toward clinical validation, with the lead program KRRO-110 for AATD now in human trials and interim data expected in late 2024. Strategic partnerships, robust preclinical data, and a clear multi-year pipeline position the company for significant milestones ahead.
Fiscal Year 2024
-
The company is advancing RNA editing therapies, with its lead AATD program set for clinical dosing in Australia in Q1 2025 and a strong cash position supporting progress into 2026. Preclinical data show robust editing, and a Novo partnership targets subcutaneous delivery for broader indications.
-
Regulatory clearance in Australia enables a global clinical program with a SAD/MAD design targeting ZZ genotype patients. Key data readouts are expected in late 2025 and 2026, with a focus on safety, pharmacokinetics, and achieving normal AAT protein levels. LNP delivery and monthly dosing aim to improve efficacy and patient convenience.
-
The presentation detailed a platform for oligonucleotide-based RNA editing, with KRRO-110 targeting Alpha-1 Antitrypsin Deficiency and first-in-human dosing planned for Q1 2025. Preclinical data show high editing efficiency and safety, with a strong team and strategic partnerships supporting pipeline growth.
-
The company is advancing RNA editing therapies, with a lead program for alpha-1 antitrypsin disease set for regulatory filing by year-end. A major partnership with Novo Nordisk expands its reach into cardiometabolic diseases, while a strong cash position supports growth into 2026.
-
The company is advancing RNA editing therapies, with a lead program in alpha-1 antitrypsin deficiency set for regulatory filing by year-end and clinical data expected next year. A new partnership with Novo Nordisk targets cardiometabolic diseases, and additional pipeline programs are in development.
-
A novel RNA editing platform enables precise, reversible genetic corrections, with lead candidate KRRO-110 showing high efficacy and specificity in preclinical models for alpha-1 antitrypsin deficiency. Regulatory filing is planned for late 2024, with clinical data expected in 2025.
-
The conference highlighted advances in RNA editing with the OPERA platform, featuring a lead candidate for alpha-1 antitrypsin deficiency showing strong preclinical efficacy and safety. Regulatory filing is planned by year-end, with clinical data expected next year.